17 September 2020 | News
China is predicted to continue its rapid bio growth rates, with more than 10 new mAbs
Image source: Shutterstock
CPhI Annual Report has launched ahead of the first CPhI Festival of Pharma (5-16 October 2020), the world’s largest digital pharma Expo that predicts dramatic growth of new mAb production in China, capacity shortages for cell and gene therapies in the USA, and the widespread global adoption of single-use technologies, but only limited continuous bioprocessing.
Three CPhI experts from BioPlan Associates – Vicky Qing XIA, Leo Cai Yang and Eric Langer – explore the rapidly changing global biologics markets, with special reference to the implications for contract outsourcing and China’s continued emergence as a hub for both bio innovation and contract services.
Remarkably, China is predicted to continue its rapid bio growth rates, with more than 10 new mAbs predicted to be launched per year in the country by 2025. In fact, the total market size will quadruple by 2025, reaching 120bn RMB, and rising further to 190bn RMB by 2030.
According to the CPhI report, bioprocessing outsourcing in China is currently highly stratified with four tiers and just one domestic company in tier one – WuXi Biologics – and a number of international CDMOs including BI, Lonza and Merck. However, by 2025 it is anticipated that as many as five more domestic CDMOs may have reached tier one status, with FDA and EU facility approvals.
Single Use Systems (SUS) are now far and away the leader at both pre-clinical and clinical stages, with nearly 85% now involving a substantial SUS component. Yet whilst its usage continues to grow, continuous bioprocessing is not anticipated to be in mainstream usage by 2025.
The report also suggested that in the US and Europe there is likely to be a cell and gene therapy capacity crunch by 2025, with CDMOs investing in this area already expanding to try and meet the pipeline’s demand.